The 5-HT 1F receptor agonist lasmiditan as a potential treatment of migraine attacks: A review of two placebo-controlled phase II trials

Journal of Headache and Pain

Volumn 13, Issue 4, 2012, Pages 271-275

  Tfelt Hansen, Peer C ^a   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 HT 1F receptor agonism; Lasmiditan; Migraine; Phase II; Randomised controlled trial

Indexed keywords

LASMIDITAN; PLACEBO; SUMATRIPTAN; 2,4,6 TRIFLUORO N (6 ((1 METHYLPIPERIDIN 4 YL)CARBONYL)PYRIDIN 2YL)BENZAMIDE; 2,4,6-TRIFLUORO-N-(6-((1-METHYLPIPERIDIN-4-YL)CARBONYL)PYRIDIN-2YL)BENZAMIDE; BENZAMIDE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST;

ANALGESIA; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DIZZINESS; DRUG BINDING; DRUG EFFICACY; FATIGUE; HUMAN; IN VITRO STUDY; MIGRAINE; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; THERAPY EFFECT; VERTIGO; ANIMAL; DOSE RESPONSE;

ANIMALS; BENZAMIDES; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; PIPERIDINES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS;

EID: 84861480975     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-012-0428-7     Document Type: Review

References (22)

1. Wolff HG (1963) Headache and other head pain. University Press, New York
2. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann N Y Acad Sci 600:587-598
3. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287 (Pubitemid 32039386)
4. MaasenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25-30
5. Tfelt-Hansen P, Seidelin K, Stepanavage M, Lines C (2002) The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. Br J Clin Pharmacol 54:38-44 (Pubitemid 36124752)
6. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for acute treatment of migraine. N Engl J Med 350:1104-1110 (Pubitemid 38298990)
7. Tfelt-Hansen P (2011) Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 51:118-123
8. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573-584
9. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R et al (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712-772
10. Villalõn CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124:309-323
11. Tfelt-Hansen PC (2012) Current understanding of calcitonin gene-related peptide (CGRP) in relation to both migraine pathophysiology and therapy. Exp Rev Neurother (in press)
12. Graham JR, Wolff HG (1938) Mechanism of migraine headache and the action of ergotamine tartrate. Arch Neurol Psychiatr 39:737-763
13. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB et al (2011) Evidence for a vascular factor in migraine. Ann Neurol 69:635-645
14. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR (2009) Neurobiology of migraine. Neuroscience 161:327-341
15. Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauass M, For the European COL-144 Investigators (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia 30:1170-1178
16. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159-1169
17. Fäkkilä M, Diener H-C, Géraud G, Lániz JM, Schoenen J, Pilgrim AJ (2010) Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain 11(Suppl 1):S43
18. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 469-503
19. Lipton RB, Hamelsky SW, Dayno JM (2002) What do patients with migraine want from acute migraine treatment? Headache 42(Suppl 1):S3-S9 (Pubitemid 34136620)
20. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW et al (2001) Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 38:1230-1234 (Pubitemid 33010848)
21. Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci USA 101:4274-4279 (Pubitemid 38405919)
22. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain (nociception) in migraine. Lancet Neurol 8:679-690